» Articles » PMID: 17671126

Triple-negative Breast Cancer: Clinical Features and Patterns of Recurrence

Overview
Journal Clin Cancer Res
Specialty Oncology
Date 2007 Aug 3
PMID 17671126
Citations 2242
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To compare the clinical features, natural history, and outcomes for women with "triple-negative" breast cancer with women with other types of breast cancer.

Experimental Design: We studied a cohort of 1,601 patients with breast cancer, diagnosed between January 1987 and December 1997 at Women's College Hospital in Toronto. Triple-negative breast cancers were defined as those that were estrogen receptor negative, progesterone receptor negative, and HER2neu negative. The prognostic significance of triple-negative breast cancer was explored.

Results: The median follow-up time of the 1,601 women was 8.1 years. One hundred and eighty of 1,601 patients (11.2%) had triple-negative breast cancer. Compared with other women with breast cancer, those with triple-negative breast cancer had an increased likelihood of distant recurrence (hazard ratio, 2.6; 95% confidence interval, 2.0-3.5; P < 0.0001) and death (hazard ratio, 3.2; 95% confidence interval, 2.3-4.5; P < 0.001) within 5 years of diagnosis but not thereafter. The pattern of recurrence was also qualitatively different; among the triple-negative group, the risk of distant recurrence peaked at approximately 3 years and declined rapidly thereafter. Among the "other" group, the recurrence risk seemed to be constant over the period of follow-up.

Conclusions: Triple-negative breast cancers have a more aggressive clinical course than other forms of breast cancer, but the adverse effect is transient.

Citing Articles

MELK as a Mediator of Stemness and Metastasis in Aggressive Subtypes of Breast Cancer.

McBean B, Abou Zeidane R, Lichtman-Mikol S, Hauk B, Speers J, Tidmore S Int J Mol Sci. 2025; 26(5).

PMID: 40076867 PMC: 11900306. DOI: 10.3390/ijms26052245.


Therapeutic potential of triple-negative breast cancer immune checkpoint blockers: A 21-year bibliometric analysis.

Sun Z, Liu C, Yao Y, Gao C, Li H, Wang L Medicine (Baltimore). 2025; 104(10):e41739.

PMID: 40068043 PMC: 11903016. DOI: 10.1097/MD.0000000000041739.


Body composition as a potential biomarker of recurrence risk in patients with triple-negative breast cancer.

De Vis J, Wang C, Nguyen K, Sun L, Jia B, Sherry A Breast Cancer Res Treat. 2025; .

PMID: 40067427 DOI: 10.1007/s10549-025-07675-w.


Optimizing Triple-Negative Breast Cancer Therapy via Ultrasound-Enhanced Piezocatalysis for Targeted Chemodrug Release.

Xue Q, He N, Gao Y, Zhang X, Li S, Chen F Int J Nanomedicine. 2025; 20:2779-2796.

PMID: 40066325 PMC: 11892375. DOI: 10.2147/IJN.S505526.


Prognostic Value of Trop-2 Expression in Nonmetastatic Triple-Negative Breast Cancer and Correlation With Emerging Biomarkers.

Jacot W, Chateau M, Thezenas S, Guiu S, Firmin N, Lafont V Cancer Med. 2025; 14(5):e70615.

PMID: 40059728 PMC: 11891490. DOI: 10.1002/cam4.70615.